• to reduce the potential risk of critical cardiovascular (heart and blood vessel) challenges in adults with variety two diabetes and heart problemsThis led Novo Nordisk to carry out further more analysis into increased dosages of semaglutide specifically for weight management.This not enough transparency only fuels the debate regarding how the c